Full Press Release Details
Patent Granted for CytoMed Therapeutics' Licensed iPSC-based Technology
Singapore - (September 25, 2023) - CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"),
a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based
allogeneic immunotherapies for the treatment of various cancers, today announced that its exclusively licensed induced pluripotent stem
cell (iPSC)-based technology has been granted a patent by the China National Intellectual Property Administration (CNIPA).
thrilled to strengthen our existing suite of patents," said Peter Choo, Chairman of CytoMed. "Now this novel iPSC-based
technology has been granted patent in China and Japan (where the iPSC technology was pioneered in 2006). Such progress further expands
the Company's current patent portfolio to three countries, consisting of and including patents granted in the US and China for
our licensed allogeneic chimeric antigen receptor gamma delta T cell (CAR- T cell) technology which is expected to start
phase I clinical trial in Singapore soon."
cancer treatment, immune cells such as T cells and natural killer (NK) cells are invaluable therapeutic cells due to their
ability to express an array of built-in receptors that recognize stress-induced cancer antigens naturally.
combining the iPSC technology and directed differentiation, CytoMed can generate a novel type of synthetic hybrid immune cells,
NKT cells, that express cancer recognition receptors of both T cells and NK cells to recognize a wide range of cancers
without genetic modification or use of viral vectors. As an allogeneic cell source, the Company's iPSC-derived NKT
cells may potentially become an "off-the-shelf" cell therapy that is applicable to a large pool of patients.
patent titled "Methods and Kits for Generating Mimetic Innate Immune Cells from Pluripotent Stem Cells" with Patent No. ZL201880022790.X,
published as CN 110691844 B, covers technologies to derive novel synthetic NKT cells for the treatment of various types
of cancers including hematological malignancies and solid tumors. This asset is currently under preclinical development. The Company
holds an exclusive, worldwide license to use this patent pursuant to the Licence Agreement dated June 1, 2018, which was filed with the
Securities and Exchange Commission as an exhibit to the registration statement on Form F-1 (File No.: 333-268456) on March 30, 2023.
CytoMed Therapeutics Limited (CytoMed)
in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore's leading research and development
agency in the public sector. It is a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create
novel cell-based immunotherapies for the treatment of human cancers. The development of novel technologies has been inspired by the clinical
success of existing CAR-T therapies in treating hematological malignancies, as well as the current clinical limitations and commercial
challenges in extrapolating the CAR-T principle into treatment of solid tumors. For more information, please visit www.cytomed.sg
press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions
and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will,
"intend," "should," "believe," "expect," "anticipate," "project,"
"estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements.
Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results
to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject
to uncertainties and risks including, but not limited to, the following: the Company's plans to develop and commercialize its product
candidates; the initiation, timing, progress and results of the Company's current and future pre-clinical studies and clinical
trials and the Company's R&D programs; the Company's expectations regarding the impact of the ongoing COVID-19 pandemic
on its business, the Company's industry and the economy; the Company's estimates regarding expenses, future revenue, capital
requirements and needs for additional financing; the Company's ability to successfully acquire or obtain licenses for additional
product candidates on reasonable terms; the Company's ability to establish and maintain collaborations and/or obtain additional
funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with
the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in
this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov.
The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that
arise after the date hereof.